Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
A Phase Ib/ii, Multicenter, Trial Of Cvx-060, A Selective Angiopoietin-2 (Ang-2) Binding, Anti-angiogenic Covx-body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/16/2015
Premiere Oncology of Arizona
mi
from
Scottsdale, AZ
A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
A Phase Ib/ii, Multicenter, Trial Of Cvx-060, A Selective Angiopoietin-2 (Ang-2) Binding, Anti-angiogenic Covx-body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/16/2015
Premiere Oncology of Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
A Phase Ib/ii, Multicenter, Trial Of Cvx-060, A Selective Angiopoietin-2 (Ang-2) Binding, Anti-angiogenic Covx-body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/16/2015
Premiere Oncology, A Medical Corporation
mi
from
Santa Monica, CA
A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
A Phase Ib/ii, Multicenter, Trial Of Cvx-060, A Selective Angiopoietin-2 (Ang-2) Binding, Anti-angiogenic Covx-body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/16/2015
Premiere Oncology, A Medical Corporation
mi
from
Santa Monica, CA
Click here to add this to my saved trials
A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
A Phase Ib/ii, Multicenter, Trial Of Cvx-060, A Selective Angiopoietin-2 (Ang-2) Binding, Anti-angiogenic Covx-body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/16/2015
Boston Baskin Cancer Foundation, Inc.
mi
from
Southaven, MS
A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
A Phase Ib/ii, Multicenter, Trial Of Cvx-060, A Selective Angiopoietin-2 (Ang-2) Binding, Anti-angiogenic Covx-body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/16/2015
Boston Baskin Cancer Foundation, Inc.
mi
from
Southaven, MS
Click here to add this to my saved trials
A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
A Phase Ib/ii, Multicenter, Trial Of Cvx-060, A Selective Angiopoietin-2 (Ang-2) Binding, Anti-angiogenic Covx-body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/16/2015
Providence Portland Medical Center
mi
from
Portland, OR
A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
A Phase Ib/ii, Multicenter, Trial Of Cvx-060, A Selective Angiopoietin-2 (Ang-2) Binding, Anti-angiogenic Covx-body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/16/2015
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
A Phase Ib/ii, Multicenter, Trial Of Cvx-060, A Selective Angiopoietin-2 (Ang-2) Binding, Anti-angiogenic Covx-body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/16/2015
Boston Baskin Cancer Foundation, Inc.
mi
from
Bartlett, TN
A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
A Phase Ib/ii, Multicenter, Trial Of Cvx-060, A Selective Angiopoietin-2 (Ang-2) Binding, Anti-angiogenic Covx-body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/16/2015
Boston Baskin Cancer Foundation, Inc.
mi
from
Bartlett, TN
Click here to add this to my saved trials
A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
A Phase Ib/ii, Multicenter, Trial Of Cvx-060, A Selective Angiopoietin-2 (Ang-2) Binding, Anti-angiogenic Covx-body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/16/2015
Boston Baskin Cancer Foundation
mi
from
Germantown, TN
A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
A Phase Ib/ii, Multicenter, Trial Of Cvx-060, A Selective Angiopoietin-2 (Ang-2) Binding, Anti-angiogenic Covx-body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/16/2015
Boston Baskin Cancer Foundation
mi
from
Germantown, TN
Click here to add this to my saved trials
A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
A Phase Ib/ii, Multicenter, Trial Of Cvx-060, A Selective Angiopoietin-2 (Ang-2) Binding, Anti-angiogenic Covx-body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/16/2015
Boston Baskin Cancer Foundation
mi
from
Memphis, TN
A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
A Phase Ib/ii, Multicenter, Trial Of Cvx-060, A Selective Angiopoietin-2 (Ang-2) Binding, Anti-angiogenic Covx-body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/16/2015
Boston Baskin Cancer Foundation
mi
from
Memphis, TN
Click here to add this to my saved trials
Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib
A Phase 2 Trial of Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib
Status: Enrolling
Updated:  10/17/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib
A Phase 2 Trial of Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib
Status: Enrolling
Updated: 10/17/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer
A Phase II Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer
Status: Enrolling
Updated:  10/17/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer
A Phase II Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer
Status: Enrolling
Updated: 10/17/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Prostate Biomarker Study
Multi-Institutional Inter-SPORE Prostate Biomarker Study
Status: Enrolling
Updated:  10/18/2015
UCLA
mi
from
Los Angeles, CA
Prostate Biomarker Study
Multi-Institutional Inter-SPORE Prostate Biomarker Study
Status: Enrolling
Updated: 10/18/2015
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Prostate Biomarker Study
Multi-Institutional Inter-SPORE Prostate Biomarker Study
Status: Enrolling
Updated:  10/18/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Prostate Biomarker Study
Multi-Institutional Inter-SPORE Prostate Biomarker Study
Status: Enrolling
Updated: 10/18/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer
Phase I/II Study of Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA) Using Lymphodepleting Conditioning Followed by Infusion of Anti-CEA TCR-Gene Engineered Lymphocytes
Status: Enrolling
Updated:  10/18/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer
Phase I/II Study of Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA) Using Lymphodepleting Conditioning Followed by Infusion of Anti-CEA TCR-Gene Engineered Lymphocytes
Status: Enrolling
Updated: 10/18/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
The Communication of Genetic Risk to Adolescent Daughters of Women With Breast Cancer
The Communication of Genetic Risk to Adolescent Daughters of Women With Breast Cancer
Status: Enrolling
Updated:  10/18/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
The Communication of Genetic Risk to Adolescent Daughters of Women With Breast Cancer
The Communication of Genetic Risk to Adolescent Daughters of Women With Breast Cancer
Status: Enrolling
Updated: 10/18/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Phase II Study of Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated:  10/18/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Phase II Study of Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated: 10/18/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Saint Edward Mercy Medical Center
mi
from
Fort Smith, AR
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Saint Edward Mercy Medical Center
mi
from
Fort Smith, AR
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Pacific Cancer Medical Center
mi
from
Anaheim, CA
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Pacific Cancer Medical Center
mi
from
Anaheim, CA
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Glendale Adventist Medical Center
mi
from
Glendale, CA
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Glendale Adventist Medical Center
mi
from
Glendale, CA
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Norris Cancer Hospital
mi
from
Los Angeles, CA
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Norris Cancer Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Clinical Trials and Research Associates, Inc.
mi
from
Montebello, CA
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Clinical Trials and Research Associates, Inc.
mi
from
Montebello, CA
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Stockton Hematology Oncology Medical Group, Inc.
mi
from
Stockton, CA
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Stockton Hematology Oncology Medical Group, Inc.
mi
from
Stockton, CA
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Pasco Hernando Oncology Associates P.A
mi
from
Brooksville, FL
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Pasco Hernando Oncology Associates P.A
mi
from
Brooksville, FL
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Pasco Hernando Oncology Associates, PA
mi
from
New Port Richey, FL
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Pasco Hernando Oncology Associates, PA
mi
from
New Port Richey, FL
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Florida Hospital Memorial System
mi
from
Ormond Beach, FL
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Florida Hospital Memorial System
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Southern Illinois Hematology/Oncology
mi
from
Centralia, IL
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Southern Illinois Hematology/Oncology
mi
from
Centralia, IL
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Rush University Medical Center
mi
from
Chicago, IL
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Joliet Oncology-Hematology Associates, Ltd.
mi
from
Joliet, IL
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Joliet Oncology-Hematology Associates, Ltd.
mi
from
Joliet, IL
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Leonard J. Chabert Medical Center
mi
from
Houma, LA
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Leonard J. Chabert Medical Center
mi
from
Houma, LA
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Sinai Hospital of Baltimore
mi
from
Baltimore, MD
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Sinai Hospital of Baltimore
mi
from
Baltimore, MD
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Oncology Care Associates, PLLC
mi
from
Saint Joseph, MI
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Oncology Care Associates, PLLC
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Deaconess Billings Clinic
mi
from
Billings, MT
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Deaconess Billings Clinic
mi
from
Billings, MT
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Nebraska Cancer Care, LLC
mi
from
Hastings, NE
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Nebraska Cancer Care, LLC
mi
from
Hastings, NE
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Southeast Nebraska Cancer Center
mi
from
Lincoln, NE
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Southeast Nebraska Cancer Center
mi
from
Lincoln, NE
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Hematology Oncology Associates of Rockland
mi
from
Nyack, NY
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Hematology Oncology Associates of Rockland
mi
from
Nyack, NY
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Carolinas Hematology-Oncology
mi
from
Charlotte, NC
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Carolinas Hematology-Oncology
mi
from
Charlotte, NC
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Signal Point Clinical Research Center, LLC
mi
from
Middletown, OH
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Signal Point Clinical Research Center, LLC
mi
from
Middletown, OH
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Southwestern Regional Medical Center
mi
from
Tulsa, OK
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Southwestern Regional Medical Center
mi
from
Tulsa, OK
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
John Peter Smith Center for Cancer Care
mi
from
Fort Worth, TX
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
John Peter Smith Center for Cancer Care
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Cedars-Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute
mi
from
Los Angeles, CA
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cedars-Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Desert Hematology Oncology Medical Group, Inc
mi
from
Rancho Mirage, CA
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Desert Hematology Oncology Medical Group, Inc
mi
from
Rancho Mirage, CA
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
University of Colorado Cancer Center
mi
from
Denver, CO
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
University of Colorado Cancer Center
mi
from
Denver, CO
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Kentucky Cancer Center
mi
from
Hazard, KY
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Kentucky Cancer Center
mi
from
Hazard, KY
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Hematology and Oncology Specialists, LLC
mi
from
Metarie, LA
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Hematology and Oncology Specialists, LLC
mi
from
Metarie, LA
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
University of Maryland, Marlene and Steward Greenbaum Cancer Center
mi
from
Baltimore, MD
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
University of Maryland, Marlene and Steward Greenbaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Lahey Clinic
mi
from
Burlington, MA
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Lahey Clinic
mi
from
Burlington, MA
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
University of Minnesota Physicians Masonic Cancer Center
mi
from
Minneapolis, MN
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
University of Minnesota Physicians Masonic Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Saint Louis University Cance Center
mi
from
Saint Louis, MO
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Saint Louis University Cance Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Big Sky Oncology, Sletten Cancer Institute
mi
from
Great Falls, MT
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Big Sky Oncology, Sletten Cancer Institute
mi
from
Great Falls, MT
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
St. Vincents Comprehensive Cancer Center
mi
from
New York, NY
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
St. Vincents Comprehensive Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials